Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06867094
Registration number
NCT06867094
Ethics application status
Date submitted
4/03/2025
Date registered
10/03/2025
Date last updated
3/07/2025
Titles & IDs
Public title
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
Query!
Scientific title
A Phase 2, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate-to-severe Ulcerative Colitis
Query!
Secondary ID [1]
0
0
U1111-1308-9729
Query!
Secondary ID [2]
0
0
DRI17822
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
SPECIFI-UC
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Colitis Ulcerative
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Inflammatory bowel disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - SAR441566
Treatment: Drugs - SAR441566 matching Placebo
Experimental: SAR441566 dose regimen 1 - Participants will receive SAR441566 dose regimen 1
Experimental: SAR441566 dose regimen 2 - Participants will receive SAR441566 dose regimen 2
Experimental: SAR441566 dose regimen 3 - Participants will receive SAR441566 dose regimen 3
Placebo comparator: Placebo - Participants will receive SAR441566-matching placebo
Treatment: Drugs: SAR441566
Pharmaceutical form: Tablet Route of administration: Oral
Treatment: Drugs: SAR441566 matching Placebo
Pharmaceutical form: Tablet Route of administration: Oral
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Proportion of participants achieving clinical remission at Week 12 by modified Mayo Score (mMS)
Query!
Assessment method [1]
0
0
Clinical remission by modified Mayo score (mMS) is defined as a mMS =2 with no subscore \>1 (stool frequency \[SF\] of 0 or 1 with at least a 1-point decrease from baseline, rectal bleeding \[RB\] of 0 and modified Mayo Endoscopic Subscore \[mMES\] of 0 or 1 where 1 does not include friability). Each component of the mMS (SF, RB, and mMES) is scored from 0 to 3. The total mMS ranges from 0 to 9 with higher scores indicating greater disease severity.
Query!
Timepoint [1]
0
0
Week 12
Query!
Secondary outcome [1]
0
0
Proportion of participants achieving clinical response at Week 12 by modified Mayo Score (mMS)
Query!
Assessment method [1]
0
0
Clinical response by modified Mayo score (mMS) is defined as a decrease from baseline in the mMS of =2 points and an improvement of =30% from baseline plus a decrease in rectal bleeding (RB) subscore =1 or an absolute RB subscore =1. Each component of the mMS (SF, RB, and mMES) is scored from 0 to 3. The total mMS ranges from 0 to 9 with higher scores indicating greater disease severity.
Query!
Timepoint [1]
0
0
Week 12
Query!
Secondary outcome [2]
0
0
Proportion of participants achieving clinical response at Week 12 by full Mayo score (MS)
Query!
Assessment method [2]
0
0
Clinical response by full Mayo score (MS) is defined as a decrease from baseline in the MS of =3 points and an improvement of =30% from baseline plus a decrease in rectal bleeding (RB) subscore =1 or an absolute RB subscore =1. The MS (also referred to as the full Mayo Score) is a composite index designed to measure ulcerative colitis (UC) disease activity and consists of 4 subscores: RB and SF, which are patient-reported subscores, Physician's global assessment (PGA), and endoscopic findings. Individual items are rated 0 to 3, giving the composite score a maximum of 12, with higher scores indicating greater disease severity.
Query!
Timepoint [2]
0
0
Week 12
Query!
Secondary outcome [3]
0
0
Proportion of participants achieving clinical remission at Week 12 by full Mayo score (MS)
Query!
Assessment method [3]
0
0
Clinical remission by full Mayo score (MS) is defined as a MS =2 with no score \>1.
Query!
Timepoint [3]
0
0
Week 12
Query!
Secondary outcome [4]
0
0
Proportion of participants achieving the combination of patient-reported outcome 2 (PRO2) remission and endoscopic remission at Week 12
Query!
Assessment method [4]
0
0
Patient-reported outcome 2 (PRO2) remission is defined as PRO2 score =1 with rectal bleeding (RB) of 0, and endoscopic remission is defined as mMES of 0. PRO2 score is defined as the sum of Mayo SF and RB subscores.
Query!
Timepoint [4]
0
0
Week 12
Query!
Secondary outcome [5]
0
0
Proportion of participants achieving endoscopic remission at Week 12
Query!
Assessment method [5]
0
0
Endoscopic remission is defined as mMES=0.
Query!
Timepoint [5]
0
0
Week 12
Query!
Secondary outcome [6]
0
0
Change from baseline in PRO2 from randomization to Week 12
Query!
Assessment method [6]
0
0
PRO2 score is defined as the sum of the Mayo SF and RB subscores.
Query!
Timepoint [6]
0
0
From Baseline to Week 12
Query!
Secondary outcome [7]
0
0
Proportion of participants achieving endoscopic response at Week 12
Query!
Assessment method [7]
0
0
Endoscopic response is defined as mMES decrease of at least 1 point.
Query!
Timepoint [7]
0
0
Week 12
Query!
Secondary outcome [8]
0
0
Proportion of participants achieving endoscopic improvement at Week 12
Query!
Assessment method [8]
0
0
Endoscopic improvement is defined as mMES of 0 or 1 where 1 does not include friability.
Query!
Timepoint [8]
0
0
Week 12
Query!
Secondary outcome [9]
0
0
Proportion of participants achieving HEMI at Week 12
Query!
Assessment method [9]
0
0
Histologic endoscopic mucosal improvement (HEMI) is defined by achievement of modified Mayo endoscopic improvement (mMES of 0 or 1 where 1 does not include friability) and histological improvement (original Geboes Score \[OGS\] =3.1).
Query!
Timepoint [9]
0
0
Week 12
Query!
Secondary outcome [10]
0
0
Plasma predose concentrations of SAR441566 at selected visits
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
Up to Week 52
Query!
Secondary outcome [11]
0
0
Plasma postdose concentrations of SAR441566 at selected visits
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
Up to Week 52
Query!
Secondary outcome [12]
0
0
Number of participants with any treatment-emergent adverse events (TEAEs) during induction and maintenance treatment period
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
Up to Week 52
Query!
Secondary outcome [13]
0
0
Number of participants with any treatment-emergent adverse events (TEAEs) during open-label treatment period
Query!
Assessment method [13]
0
0
Query!
Timepoint [13]
0
0
From Week 12 to Week 52
Query!
Secondary outcome [14]
0
0
Proportion achieving Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 12
Query!
Assessment method [14]
0
0
Inflammatory Bowel Disease Questionnaire (IBDQ) remission is considered as an IBDQ-32 total score =170 points. IBDQ is designed to capture the patient's experience of IBD on 4 domains of functioning and well-being: bowel and systemic symptoms and emotional and social function. The total IBDQ score ranges from 32 to 224 which indicates better quality of life.
Query!
Timepoint [14]
0
0
Week 12
Query!
Secondary outcome [15]
0
0
Proportion of participants achieving Inflammatory Bowel Disease Questionnaire (IBDQ) response at Week 12
Query!
Assessment method [15]
0
0
Inflammatory Bowel Disease Questionnaire (IBDQ) response is defined as an increase from baseline in the total IBDQ score in the range of 16 to 32 points.
Query!
Timepoint [15]
0
0
Week 12
Query!
Secondary outcome [16]
0
0
Inflammatory Bowel Disease Questionnaire (IBDQ) response is defined as an increase from baseline in the total IBDQ score in the range of 16 to 32 points.
Query!
Assessment method [16]
0
0
Query!
Timepoint [16]
0
0
Week 12
Query!
Eligibility
Key inclusion criteria
Participants are eligible to be included in the study only if all of the following criteria apply:
* Male or female participants aged 18 to 75 years inclusive, at the time of signing the informed consent
* Participants who have clinical evidence of active UC for =3 months before screening and confirmed by endoscopy during the screening period
* Active moderate-to-severe UC at screening as defined by a modified Mayo Score (mMS) of 5 to 9 (without the Physician global Assessment (PGA), with a minimum rectal bleeding (RB) subscore =1, a minimum stool frequency (SF) subscore =1, a mMES =2 confirmed by central reader, a minimum sum of all subscores of 5, and a disease extent >15 cm from the anal verge
* Must have received prior treatment for UC (either "a" or "b" below or combination of both):
1. No prior exposure to Advanced Therapy (AT), but having inadequate response to, loss of response to or intolerance to standard treatment with any of the following compounds: 5-ASA, 6-MP, AZA, MTX, oral or intravenous (IV) corticosteroids or history of corticosteroid dependence (defined an inability to successfully taper corticosteroids without recurrence of UC) OR
2. Inadequate response to, loss of response to or intolerance to treatment with =1 approved AT such as a biologic agent (such as TNF antagonists, anti-integrin other than natalizumab, anti-IL-12/23, anti-IL-23, or experimental biologic UC therapeutics), or a small molecule (such as a JAKi or S1PRm) for UC
* Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Participants are excluded from the study if any of the following criteria apply:
* Participants with active CD, indeterminate colitis, ischemic colitis, microscopic colitis
* Participants with the following ongoing known complications of UC: fulminant colitis, toxic megacolon, or any other manifestation that might require bowel surgery while enrolled in the study
* Participant with prior colectomy, ostomy or ileoanal pouch, or anticipated colectomy during their participation in the study
* Participants with fecal sample positive for ova or parasites, bacterial pathogens, or positive for Clostridium difficile B toxin in stools
* Participants with active tuberculosis (TB) or a history of incompletely treated active TB or latent TB infection per local guidelines
* Participants with Positive Hepatitis B surface antigen (HBsAg), or Hepatitis B core antibody (HBcAb) and/or Hepatitis C virus antibody (HCVAb) at the screening visit
* Participants with any other active, chronic or recurrent infection, including recurrent or disseminated herpes zoster or disseminated herpes simplex
* Participants with a known history of human immunodeficiency virus (HIV) infection or positive HIV-1 or HIV-2 serology at screening
* Participants presenting with active malignancies, lymphoproliferative disease, or recurrence of either, within the 5 years before screening
* If the participant has extensive colitis for =8 years or disease limited to left side of colon (ie, distal to splenic flexure) for >10 years, regardless of age, a colonoscopy within 1 year of the screening visit is required to survey for dysplasia. Participants with dysplasia or cancer identified on biopsies will be excluded.
* Female participants who is pregnant, breastfeeding, or is considering becoming pregnant during the study or within 3 months after the last dose of study drug
* Infection(s) requiring treatment with IV anti-infectives within 30 days prior to the screening visit or oral/intramuscular anti-infectives within 14 days prior to the screening visit
* Participants requiring or receiving any parental nutrition and/or exclusive enteral nutrition
* Participants who received cyclosporine, tacrolimus, mycophenolate mofetil, or thalidomide within 30 days prior to screening
* Participants who received fecal microbial transplantation within 30 days prior to screening
* Participants who have ever been exposed to natalizumab (Tysabri®) or oral carotegrast methyl (Carogra®)
* Participants who received IV corticosteroids within 14 days prior to screening or during screening period
* Screening laboratory and other analyses show abnormal results.
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
28/03/2025
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
11/05/2028
Query!
Actual
Query!
Sample size
Target
204
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
QLD
Query!
Recruitment hospital [1]
0
0
Investigational Site Number : 0360001 - Mackay
Query!
Recruitment postcode(s) [1]
0
0
4740 - Mackay
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Connecticut
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Illinois
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Michigan
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
New York
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Pennsylvania
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Texas
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Washington
Query!
Country [10]
0
0
Argentina
Query!
State/province [10]
0
0
Buenos Aires
Query!
Country [11]
0
0
Belgium
Query!
State/province [11]
0
0
Gent
Query!
Country [12]
0
0
Belgium
Query!
State/province [12]
0
0
Leuven
Query!
Country [13]
0
0
Canada
Query!
State/province [13]
0
0
Nova Scotia
Query!
Country [14]
0
0
Canada
Query!
State/province [14]
0
0
Québec City
Query!
Country [15]
0
0
Chile
Query!
State/province [15]
0
0
Reg Metropolitana De Santiago
Query!
Country [16]
0
0
Czechia
Query!
State/province [16]
0
0
Olomouc
Query!
Country [17]
0
0
Japan
Query!
State/province [17]
0
0
Chiba
Query!
Country [18]
0
0
Japan
Query!
State/province [18]
0
0
Niigata
Query!
Country [19]
0
0
Japan
Query!
State/province [19]
0
0
Hiroshima
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Sanofi
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe UC. The primary objective of this study is to assess efficacy of different doses of SAR441566 on clinical remission in participants with moderate-to-severe ulcerative colitis. This study will include a screening period of up to 28 days (+ 7 calendar days if needed) followed by the main study treatment period of 52 weeks which will be comprised of a double blind (DB) treatment period with 12 weeks of induction period followed by a maintenance period of 40 weeks and 2-week follow-up after end of treatment. Additionally, an Open Label (OL) period of up to 40 weeks will be offered to eligible participants. * The study duration will be up to 59 weeks. * The treatment duration will be up to 52 weeks in the DB arm and up to 40 weeks in the OL arm. * The number of visits will be 12 for the main study treatment period and 8 for the OL treatment period.
Query!
Trial website
https://clinicaltrials.gov/study/NCT06867094
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Trial Transparency email recommended (Toll free for US & Canada)
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
800-633-1610
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Query!
When will data be available (start and end dates)?
Query!
Available to whom?
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06867094
Download to PDF